Welcome to our dedicated page for Ayala Pharm news (Ticker: ADXS), a resource for investors and traders seeking the latest updates and insights on Ayala Pharm stock.
Ayala Pharmaceuticals (ADXS) is a clinical-stage biotech company pioneering novel cancer immunotherapies and small molecule treatments targeting rare tumors and aggressive cancers. This dedicated news hub provides investors and healthcare professionals with timely updates on clinical developments, regulatory milestones, and strategic partnerships.
Our curated collection features official press releases, trial result announcements, and expert analyses of ADXS's proprietary bacterial-based immunotherapy platform. Key focus areas include advancements in modifying the tumor microenvironment, progress across the company's oncology pipeline, and collaborations advancing next-generation cancer therapies.
Users can expect comprehensive coverage of:
• Clinical trial updates for immunotherapy candidates
• Strategic partnership announcements with biopharma leaders
• Regulatory developments across global markets
• Scientific presentations at major oncology conferences
Bookmark this page for verified updates on Ayala Pharm's progress in developing treatments that harness the immune system to combat challenging cancers. Check regularly for new insights into their dual-platform approach combining bacterial vectors and targeted small molecules.
OS Therapies (NYSE-A: OSTX) has entered into an asset purchase agreement to acquire listeria monocytogenes-based immuno-oncology programs and IP assets from Ayala Pharmaceuticals. The acquisition includes a Phase 2 lung cancer and Phase 1 prostate cancer program, along with direct ownership of IP related to OST-HER2 for osteosarcoma.
The deal, valued at $0.5 million in cash and $7.5 million in OSTX shares, eliminates milestone payments and reduces royalty obligations for OST-HER2. The company recently secured $7.1 million in financing at $4.00 per share, providing cash runway into 2026. The monthly burn rate is approximately $0.4M.
OS Therapies plans to request BLA for OST-HER2 in osteosarcoma in Q2 2025, with potential approval and Priority Review Voucher by end of 2025. The company is prohibited from issuing shares for 6 months and suspended equity line usage below $12.00 per share.
OS Therapies (NYSE-A: OSTX) has entered an asset purchase agreement to acquire listeria monocytogenes-based immuno-oncology programs and IP assets from Ayala Pharmaceuticals. The acquisition includes a Phase 2 lung cancer and Phase 1 prostate cancer program, along with direct ownership of IP related to OST-HER2 for osteosarcoma.
The deal involves a $0.5 million cash payment and $7.5 million in OSTX common shares. The company recently secured $7.1 million in financing at $4.00 per share, providing cash runway into 2026. OS Therapies plans to request BLA for OST-HER2 in osteosarcoma in Q2 2025, with potential FDA approval and Priority Review Voucher by end of 2025.
The agreement eliminates milestone payment obligations and reduces royalty rates for OST-HER2. The company's current burn rate is approximately $0.4M monthly, and they are prohibited from issuing shares for capital raising for 6 months and below $12.00 per share.
Ayala Pharmaceuticals, a clinical-stage oncology company, has filed a Form 15 with the SEC to deregister its common stock under the Exchange Act and suspend reporting obligations. This move will make the company no longer a public reporting entity once the Form 15 is effective.
